Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares, rose in value, with the stock price up by 2.84% to the previous day’s close as strong demand from buyers drove the stock to $30.42.
Actively observing the price movement in the last trading, the stock closed the session at $29.58, falling within a range of $29.43 and $30.58. The value of beta (5-year monthly) was 0.375. Referring to stock’s 52-week performance, its high was $62.53, and the low was $24.10. On the whole, CRNX has fluctuated by -12.26% over the past month.
With the market capitalization of Crinetics Pharmaceuticals Inc currently standing at about $2.83 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 100k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRNX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CRNX currently trading nearly -1.21% and -8.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.89, while the 7-day volatility ratio is showing 5.72% which for the 30-day chart, stands at 6.85%. Furthermore, Crinetics Pharmaceuticals Inc (CRNX)’s beta value is 0.38, and its average true range (ATR) is 1.96.
A comparison of Crinetics Pharmaceuticals Inc (CRNX) with its peers suggests the former has fared considerably weaker in the market. CRNX showed an intraday change of 2.84% in last session, and over the past year, it shrunk by -30.05%%.
Data on historical trading for Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) indicates that the trading volumes over the past 10 days have averaged 1.12 and over the past 3 months, they’ve averaged 1.03 million. According to company’s latest data on outstanding shares, there are 92.93 million shares outstanding.
Nearly 6.99% of Crinetics Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 104.67% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.54 million shares as on 2025-03-31, resulting in a short ratio of 7.96. According to the data, the short interest in Crinetics Pharmaceuticals Inc (CRNX) stood at 934.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 8.11 million. The stock has fallen by -40.50% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRNX stock heading into the next quarter.
